To bring the best possible therapeutics to the most patients in China within the shortest time - this is the commitment Gilead Sciences has to China since its China operations launched in 2016. This commitment is endorsed by the global vision of Gilead as to advance therapeutics against life-threatening diseases worldwide. It is also reflected in the everyday job that the Gilead team has been delivering in China.

We have launched eight globally advanced and innovative therapeutics in China for HBV, HCV and HIV/AIDS to help address unmet medical needs. These therapeutics are Sovaldi® (Sofosbuvir), Epclusa® (Sofosbuvir/Velpatasvir), Genvoya®(E/C/F/TAF), Vemlidy® (TAF), Harvoni® (Ledipasvir/Sofosbuvir), Descovy®(F/TAF) ,Truvada® (FTC/TDF) and Biktarvy®(BIC/FTC/TAF). As we further grow and develop our China affiliate, we strive to introduce more of our global leading treatments to help patients in China and to contribute to the improvement of the public health on the ground.

Gilead China is headquartered in Shanghai. Today, we have approximately 300 employees in more than 40 cities, and we are still expanding our China team.

Contact Information

Public Affairs
+86 21 3893 4588
[email protected]